Anju Software, a leading provider of clinical trials and commercial operations solutions, has acquired OmniComm Systems (OTC:OMCM), a strategic software solutions provider to the life sciences industry.
- The transaction positions the combined organization as a leader in the eClinical solutions market, with particular expertise in electronic data capture and eSource
- OmniComm’s solutions, including its flagship TrialMaster® and TrialOne® products, will complement Anju’s existing solution suite
- Upon closing, shares of OmniComm common stock will be cancelled and automatically converted into the right to receive $0.41032 per share, without interest, representing an 58% premium to the closing price on July 15, 2019
About Anju Software
Anju Software is a leading provider of comprehensive software solutions to the life sciences industry. Anju provides an integrated platform spanning clinical, medical affairs and commercial operations. Anju solutions are used by large and small pharmaceutical companies, clinical research organizations (CRO), full service agencies and medical device companies. Data flow between functional areas, seamless communication with third party systems and AI-based data mining solutions to provide customers critical information throughout their ecosystem.
About OmniComm Systems (OTC: OMCM)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors principally located in the United States, Europe, and East Asia. OmniComm’s proprietary EDC and eClinical software applications – TrialMaster®, TrialOne®, eClinical Suite, Promasys®, IRTMaster, AutoEncoder, and Acuity – allow clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical trial data.
About ABRY Partners
Since its founding in 1989, Abry has focused on media, communications, business and information services to become one of the most experienced private equity firms investing in North America and Europe. Abry’s funds are deployed by our close-knit and diverse team of professionals, most of whom have built their careers at the firm.
Client Highlights
- 9 Transactions
- 6 Year Partnership
Transaction Details
-
SectorsHealthcare & Life Sciences Technologies
-
ServiceCorporate Strategy
-
OwnershipInvestor-Backed
-
Practices
Healthcare & Life Sciences Technology
Sponsor Coverage